Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 86. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
From little subclones grow mighty oaks1340
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC1303
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC913
Sacituzumab govitecan plus pembrolizumab improves outcomes904
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma867
A new standard of care for advanced-stage urothelial carcinoma736
Novel ICI–TKI combination improves HCC outcomes715
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles633
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes594
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown589
Ecological management of the microbiota in patients with cancer552
Hodgkin lymphoma: great progress with room for improvement540
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime524
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines510
Gut microbiota in colorectal cancer development and therapy503
Current understanding and management of CAR T cell-associated toxicities495
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials436
Ponatinib superior to imatinib in Ph+ ALL408
Mortality is similar with active monitoring373
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials352
From ESMO 2022352
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence350
Belzutifan as a new option in pheochromocytomas and paragangliomas350
Sacituzumab tirumotecan improves OS in mTNBC342
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC342
Humanized mouse models for immuno-oncology research341
Emerging trends in the global burden of colorectal cancer341
Minimal residual disease as a target for liquid biopsy in patients with solid tumours334
Understanding and overcoming multidrug resistance in cancer330
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC314
Biomarkers for immunotherapy of hepatocellular carcinoma305
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours286
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer283
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs279
Vebreltinib effective in MET-amplified NSCLC266
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease264
Improving outcomes in patients with oesophageal cancer264
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma264
Spatial landscapes of cancers: insights and opportunities231
MicroRNAs in oncology: a translational perspective in the era of AI227
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response218
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests216
Unresectable stage III non-small-cell lung cancer: state of the art and challenges206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship206
Approvals in 2022: overall survival, dose optimization, new approvals and beyond202
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC196
Women with clinically node negative breast cancer can safely avoid axillary surgery184
Domvanalimab plus zimberelimab shows promise in upper-tract cancers182
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’182
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma177
Prospective comparisons support the use of navigational bronchoscopy171
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC155
DREAMseq of therapy for BRAF-mutant melanoma154
From ESMO 2023: advances in lung cancer153
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA149
Targeting chromosomal instability in patients with cancer149
Synergistic integration of regional and systemic therapies in uveal melanoma144
Circulating tumour DNA — looking beyond the blood142
Mitigating acute chemotherapy-associated adverse events in patients with cancer138
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM132
Long-term outcomes following CAR T cell therapy: what we know so far132
Multiomics STEP up in correlative analysis of response to CAR T cells130
From the ESMO Congress 2023129
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas127
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress126
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC124
Sentinel lymph node biopsy improves surgical management of cervical cancer121
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL120
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma117
Author Correction: Innovative approaches for lung cancer screening and interception115
Lung cancer in patients who have never smoked — an emerging disease114
Newly approved cancer drugs in China — innovation and clinical benefit111
Enhancing immunotherapy with tumour-responsive nanomaterials110
Targeted biopsy reduces detection of clinically insignificant cancer110
Claudin 18.2 as a novel therapeutic target110
Clinical implications of T cell exhaustion for cancer immunotherapy110
T-DXd effective as second-line therapy in G/GEJ cancers108
Second-line tarlatamab improves OS in SCLC106
Less-frequent surveillance is noninferior to annual mammography105
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC103
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy103
Translating biological insights into improved management of endometrial cancer98
Patient value over patent value: the mandate for open-source oncology94
Barriers in access to oncology drugs — a global crisis90
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology89
Two decades of advances in clinical oncology — lessons learned and future directions87
0.051275014877319